Global

While it is foundational to commercial operations, most European life sciences companies are not getting what they need from their customer data, writes Guillame Roussel.

March 20, 2017

It is hard to resist the sensation that the rhetoric of that Shakespeare's Henry V is informing much of the Brexit thinking in Westminster, writes Reflector.

NICE and NHSE have been grappling with the issue of affordability. It’s not a new challenge, but with the advent of new treatments that are both cost effective and unaffordable, something has to be done. Leela Barham reports.

Pharm Exec talks to Hugo Fry, Sanofi’s General Manager for the UK and General Manager for Sanofi Pasteur UK and Ireland, about his vision for the company and the vaccine space in these markets.

March 07, 2017

The European Commission's latest economic assessment of EU member states does not make for comfortable reading, writes Reflector.

Pharm Exec speaks to Chris Molloy, CEO of the newly established Medicines Discovery Catapult, which aims to establish new approaches to grow and sustain the UK's reputation for innovative, fast-to-patient drug discovery.

March 03, 2017

Leela Barham looks at NICE's new position statement, which seeks to set out a little more clearly how it works with industry.

March 01, 2017

March 01, 2017

Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry

February 28, 2017

With a population of just 4.7 million and a landmass smaller than the state of Indiana, the republic of Ireland stands as an unlikely pharmaceutical manufacturing powerhouse.

February 23, 2017

February 22, 2017

February 22, 2017

Global market access analyst Neil Grubert discusses what are likely to be some of the key trends in market access this year and beyond, and the implications for the life sciences industry.

Outlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.

February 17, 2017

The populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.

Pharm Exec talks to Mel Formica, Takeda’s Vice President of Global Market Access, about what he sees as the challenges and opportunities in 2017, and how he envisions the industries market access capabilities evolving.

Pharm Exec speaks to ICON's Ramita Tandon about how the UK and European regulators' market access plans for 2017 will affect the industry.

With the push toward value-based heathcare set to accelerate even more in 2017, Takeda’s VP of global market access discusses the evolution of this all-important engine for medical innovation and bottom-line returns.

Pharm Exec speaks with Ramita Tandon, executive vice president, ICON Commercialization & Outcomes, about the potential impact of UK and European regulators’ market access plans for the industry.

Despite serving as a regional hub for numerous leading global healthcare and life sciences companies-while simultaneously straddling the frontier of biomedical advancement and innovation-Singapore is reinventing itself yet again and spearheading a new model of Asian healthcare.

As the healthcare landscape evolves, pharmaceutical companies are being driven to embrace new, unique partnerships to go beyond the pill, writes Weng Si Ho.

The long-cherished dream of finding a European approach to assessing the value of new medicines seems to recede further with every step taken to pursue it, writes Reflector.

The Lancet's series of papers on moving from universal health care coverage to "right care" for health offers a truly global and comprehensive perspective, writes Leela Barham. But just what does "right care for health" mean for the industry?